Enteris touts early-stage oral peptide delivery for pain; Iran researchers develop material for targeted delivery;

> Enteris BioPharma reported successful results in a Phase I trial of its oral delivery method for Cara Therapeutics' CR845 peptide for acute and chronic pain. Release

> Researchers in Iran have developed hydrophobic polysaccharides for drug delivery. The material showed lower toxicity for healthy cells, and the researchers were able to target its paclitaxel load to release at the site of a tumor using biotin. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.